CClinicalTrials.gg
CompletedNCT03287154ITAMAAUpdated Jan 13, 2026

Interest of tDCS in Help for Supporting Alcohol Abstinence

An interventional study of Active tDCS stimulations and Sham tDCS in Alcoholic Intoxication, sponsored by Centre Hospitalier Henri Laborit. Completed at 2 sites in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Centre Hospitalier Henri Laborit · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of the study is to evaluate in patients with alcohol disorder and forehand weaned the efficiency of 10 active tDCS sessions versus 10 sham (placebo) sessions in the support of abstinence at 3 months.

Read the detailed description

The study takes place at one site (Henri Laborit Hospital, Poitiers, France) and is comparative, randomized and controlled.

There are 2 groups : one group is receiving sessions of active tDCS (active group) whereas the second group is receiving sham (placebo) sessions (control group).

Patients are randomized either in the active group or in the control group with a 1:1 ratio.

An unblinded investigator is responsible of the stimulation part and could not evaluate the patients. The other investigators are blinded and could evaluate the patients.

The study is going to evaluate the effect produces by stimulations in the two groups.

In the placebo group, after the intensity has reached its maximal intensity (the same as in the active group), the stimulation is stopped after few seconds (30 seconds in mostly studies). This process allow patients in the placebo group to feel the same sensations as patients in the active group (indeed, tingles and itches are felt only during the first few seconds of stimulation). The poor duration of stimulation do not produces clinical effect.

The study begins after a withdrawal period of 7 days +/- 3 days with 10 stimulations of 2 mA during 20 minutes from Monday to Friday during 2 weeks.

Following these stimulation sessions, the patient will have 5 follow-up visits on site with an investigator and 2 phone follow-up.

Visits:

  • Pre-inclusion visit
  • V0 visit (inclusion visit): takes place at the earliest 48 hours after stopping benzodiazepines used in the withdrawal period.
  • Treatment (weeks 0 and 1): 5 days of treatment per week during 2 weeks 2 arms : sham (placebo, 10 stimulations) vs active (10 stimulations of 2 mA)
  • Visit 1 (Week 4) : short nurse consultation
  • Visit 2 (Week 6) : short medical consultation
  • Visit 3 (Week 10) : short medical consultation
  • Visit 4 (Week 14) : long medical consultation
  • Visit 5 (Week 18) : nurse phone follow-up
  • Visit 6 (Week 22) : nurse phone follow-up
  • Visit 7 (Week 26) : long medical consultation
02

Conditions studied

  • Alcoholic Intoxication

Keywords

  • Alcohol Abstinence
  • Alcohol Addiction
  • Alcohol Consumption
  • Alcohol Dependence
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patient aged from 18 to 70 years old
  • patient free, without guardianship
  • absence of epileptic pathology
  • patient affiliated to the french health security or benefiting through a third party
  • signed informed consent after having received a clear and honest information on the study.
  • patient with a disorder linked to the use of alcohol (define by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) classification) clinically evaluated.
  • patient requesting for an alcohol withdrawal
  • patient able to read and write

Exclusion criteria

Exclusion Criteria:

  • patient not affiliated to the french health security or not benefiting through a third party
  • woman in reproductive capacity without effective contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intra-uterine device or chirurgical: tubal ligation, hysterectomy, total ovariectomy) or breastfeeding
  • patient hospitalized under duress
  • patient with guardianship
  • somatic complications during the alcohol withdrawal phase
  • current psychiatric decompensation (mood disorder, suicide risk, psychotic disorders).
  • patient under benzodiazepines treatment
  • patient with scalp cutaneous lesion
  • history of cranial traumatism
  • patient with intra-cerebral metallic object
  • patient with a pacemaker
  • epileptic pathology
  • patient in emergency condition or unable to give personally her/his consent
  • another dependence other than alcohol or tobacco
  • mental illness syndrome and Korsakoff
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Active tDCS stimulations

    Patients in this arm will receive 10 tDCS active stimulations of 2 mA (1 stimulation per day from Monday to Friday during 2 weeks).

    Device: Active tDCS stimulations

  • Sham comparator
    Sham tDCS

    Patients in this arm will receive 10 sham stimulations (1 stimulation per day from Monday to Friday during 2 weeks). As soon as the power will have reached the maximal intensity as in the active arm, the stimulation will be stopped.

    Device: Sham tDCS

Interventions

  • DeviceActive tDCS stimulations

    20 min, 2mA

  • DeviceSham tDCS

    20 min, Sham

05

What researchers measure

Primary outcomes

  1. Alcohol Abstinence

    The primary outcome is to evaluate the interest of the transcranial Direct Current Stimulation (tDCS) for helping the abstinence support in addictive alcoholic patients.

    Time frame: 3 months

Secondary outcomes

  1. Relapse control

    Evaluation of tDCS interest in help for relapse control.

    Time frame: 6 months

  2. Alcohol consumption

    Impact on alcohol consumption based on the Total Alcohol Consumption (TAC).

    Time frame: 6 months

  3. Anxiety-depression

    Impact on the anxiety-depression symptomatology

    Time frame: 6 months

  4. Tobacco consumption

    Impact on tobacco consumption (decrease of cigarette consumption).

    Time frame: 6 months

  5. Safety assessment with adverse and/or intercurrent events analysis.

    The clinical tolerability will be objectified through the analysis of adverse and /or intercurrent events occuring all along the study. Theses events will be assessed at every study visit during patient examination.

    Time frame: 6 months

  6. Cognitive functions assessments with the Moca-test questionnaire.

    The score to the Moca-test will permit to assessed the cognitive functions from baseline (week 0) to the week 14 and from baseline from the week 26.

    Time frame: 6 months

  7. Executive functions assessments with the scale Barratt Impulsiveness Scale (BIS 11).

    This examination will be assessed from week 0 to Day 9, from week 0 to week 14 and from week 0 to week 26.

    Time frame: 6 months

  8. Executive functions assessments with the Go NoGo task.

    This examination will be assessed from week 0 to Day 9, from week 0 to week 14 and from week 0 to week 26.

    Time frame: 6 months

  9. Executive functions assessments with the Wisconsin Card Sorting Test (WCST).

    This examination will be assessed from week 0 to Day 9, from week 0 to week 14 and from week 0 to week 26.

    Time frame: 6 months

  10. Executive functions assessments with the Stroop test.

    This examination will be assessed from week 0 to Day 9, from week 0 to week 14 and from week 0 to week 26.

    Time frame: 6 months

  11. Executive functions assessments with the IOWA Gambling Task (IGT).

    This examination will be assessed from week 0 to Day 9, from week 0 to week 14 and from week 0 to week 26.

    Time frame: 6 months

06

Study locations

2 sites
  • Centre Hospitalier Henri Laborit
    Poitiers, France
  • Centre Hospitalier Nord-Deux-Sèvres
    Thouars, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03287154
Lead sponsor
Centre Hospitalier Henri Laborit
Responsible party
Sponsor
First posted
Sep 19, 2017
Start date
Feb 8, 2017
Primary completion
Feb 7, 2025
Completion
Aug 7, 2025
Last update
Jan 13, 2026

Study contacts

Nematollah Jaafari, Professor
principal investigator · Centre Hospitalier Henri Laborit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion